NEW YORK & ARMONK, N.Y.–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) and IBM (NYSE:IBM) today announced a first-of-its-kind research collaboration to develop innovative remote monitoring solutions aimed at transforming how clinicians deliver care to patients suffering from Parkinson’s disease. The experimental approach will rely on a system of sensors, mobile devices, and machine learning to provide real-time, around-the-clock disease symptom information to clinicians and researchers. The ultimate goal is to obtain a better understanding of a patient’s disease progression and medication response to help inform treatment decisions and clinical trial design, while also speeding the development of new therapeutic options. Parkinson’s disease in particular requires ongoing adjustment to medication depending on the progression of the disease and response of the patient. The collaboration seeks to create a holistic view of a patient’s well-being…